Overview

Anlotinib Capsules in the Treatment for IPF/PF-ILDs

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The use of Anlotinib hydrochloride capsules for the treatment of IPF/PF-ILDs, with FVC as the primary efficacy endpoint to evaluate its effectivenes
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
First Affiliated Hospital of Wenzhou Medical University
Collaborator:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.